Product
Colistin
7 clinical trials
13 indications
Indication
Acinetobacter baumanniiIndication
Hospital-acquired Bacterial PneumoniaIndication
Ventilator-associated PneumoniaIndication
BacteremiaIndication
Colistin Resistant ABCIndication
Acute Kidney InjuryIndication
Drug-Induced NephropathyIndication
Polymyxin EIndication
Carbapenem Resistant Bacterial InfectionIndication
Acinetobacter baumannii BacteremiaIndication
Acinetobacter PneumoniaIndication
Cystic FibrosisClinical trial
A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus ComplexStatus: Completed, Estimated PCD: 2021-07-26
Clinical trial
The Effect of Curcumin Against Colistin-induced NephrotoxicityStatus: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane OxygenationStatus: Terminated, Estimated PCD: 2024-01-19
Clinical trial
Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection：a Prospective, Open-label, Randomized Controlled, Multicenter Clinical TrialStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
IV Colistin for Pulmonary Exacerbations: Improving Safety and EfficacyStatus: Completed, Estimated PCD: 2020-09-10
Clinical trial
Ceftazidime-Avibactam Versus Colistin in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections (AVI-ICU): A Non-Inferiority Randomized Clinical TrialStatus: Terminated, Estimated PCD: 2023-04-12